Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    A Brief Note About Alzheimer’s

    Well, there it is. Biogen and Eisai have announced just this morning that they’re halting Phase III trials of aducanumab, their anti-amyloid antibody, after the monitoring committee judged that further treatment would be futile. I’m not going to do some sort of victory dance, because (once again) this is bad news for Alzheimer’s… Read More
  • Alzheimer's Disease

    Another Alzheimer’s Antibody Fails. There Will Be More.

    To what should be absolutely no human being’s surprise, another amyloid-antibody trial has failed. Roche announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. They’re still going on with a study in familial early-onset disease in Colombia, and they ha… Read More
  • Alzheimer's Disease

    A New Infectious Mechanism for Alzheimer’s?

    We have another entry in the “Is Alzheimer’s caused by infectious disease?” drawing, and it’s a good one. A large multicenter team reports that Porphyromonas gingivalis, which is the key pathogen in gingivitis (gum disease) may be the actual causative agent in Alzheimer’s, which is a bold claim indeed. But they have… Read More
  • Alzheimer's Disease

    The Genomics of Neurons. And Alzheimer’s. And Everything Else.

    The brain is a complicated organ. Let’s start there. It’s complicated at every level that you care to examine, and if you get down to the genomic sequences of individual neurons, it’s worse than ever. The sheer variety of neurons and other cell types is quite extreme, and a lot of work over the years… Read More
  • Alzheimer's Disease

    Failure Shouldn’t Be Such an Orphan

    The drug industry has  a huge stockpile of results on projects that have not worked. That much is clear – clinical success rates continue at about 10%, on average, so we have a steady stream failures of all kinds, for all reasons. It would be foolish not to learn as much as we could from… Read More
  • Alzheimer's Disease

    More on BAN2401, Unfortunately

    If you’re interested in Alzheimer’s clinical trials, and especially in the Biogen/Eisai antibody (BAN2401) that I last wrote about here, today has been a big day. But maybe not a good day. That last post from from July, when the two companies had released data about the BAN2401 trials, and a lot of questions were… Read More
  • Alzheimer's Disease

    Biogen and Eisai: Let the Alzheimer’s Arguing Commence

    Well, the tease is over: Biogen and Eisai have released data on their Alzheimer’s antibody, BAN2401. And the situation is messy, as many had feared. The top-line results are mostly positive, but there are several confounding factors that make them a matter of argument (see below). The companies were scheduled to go public with the… Read More
  • Alzheimer's Disease

    The Case of Verge Genomics

    A number of people have passed along the recent press stories about Verge Genomics, a new company out of YCombinator that has just raised $32 million for neuroscience drug discovery. Now that, as literally anyone who’s ever done it can tell you, is a hard field of a hard field, and I wish Verge good… Read More
  • Alzheimer's Disease

    Biogen And Eisai Tease an Alzheimer’s Result

    OK, we have kind of a complicated situation today. Biogen and Eisai have press-released what appear to be positive results for an anti-amyloid antibody therapy for Alzheimer’s. Since every single other attempt in this area has failed, often at great expense, what are we to make of this? Well, the first thing to say is… Read More
  • Alzheimer's Disease

    Alzheimer’s and Infectious Disease: For Real

    I’ve written a couple of times over the years about the idea that Alzheimer’s disease might have an infectious component to it. That’s been proposed many times, but it’s fair to say that it’s never caught on. For one thing, the amyloid hypothesis has always had a lot more going for it. I realize that… Read More
123...